Cell behaviour, differentiation and manufacturing
Director: Professor Peter Andrews, University of Sheffield
The key focus of this Hub is to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. The Hub will build upon emerging technologies to optimise processes for consistent, scalable stem cell manufacturing that minimize the appearance of genetic and epigenetic variants, and meet the requirements of clinicians, regulatory authorities and industry for safe and cost-effective applications. More..
Engineering and exploiting the stem cell niche
Director: Professor Stuart Forbes, University of Edinburgh
The key focus of this Hub is to exploit therapeutically our understanding of the biology of stem niches. The niche (“the soil”) that surrounds stem/progenitor cells (“the seed”) in developing or damaged organs has a profound effect upon the stem/progenitor cells. We will use this knowledge to optimise the growth and differentiation of stem cells and improve organ regeneration through endogenous repair and cell transplantation. More..
Safety and efficacy, focussing on imaging technologies
Director: Professor Kevin Park, University of Liverpool
The key focus of this Hub is to provide a clearer understanding of the potential hazards (and associated risks) with RMTs and to develop new methodologies to assess their risk, so that scientific stakeholders are able to accelerate these new medicines into the human population with full confidence. More..
Acellular (smart material) approaches for therapeutic delivery
Director: Professor Kevin Shakesheff, University of Nottingham
The key focus of this Hub is to develop platform technologies that use materials and drugs to orchestrate cells to regenerate tissue. In regenerative medicine applications, the cells that generate new tissue can either reside within the patient or be administered as a therapy. In both cases there is a need to create an environment in vivo that facilitiates tissue formation. Therapeutic delivery systems build on principles of biomaterials design and drug delivery to create final products in which the efficacy of cell therapies or the mobilisation of the patient’s own stem cells are maximised. More..
Director: Professor Fiona M Watt, King’s College London
The key focus of this Hub is to discover how to harness the immune system for improved outcomes in regenerative medicine. The central goal of regenerative medicine is to replace damaged or diseased tissue. This can potentially be achieved by stimulating endogenous tissue repair or by transplanting autologous or allogeneic cells. No matter which strategy is taken, host immune responses can represent a formidable obstacle to success. By modulating different aspects of the immune system we intend to improve the efficacy of regenerative medicine therapies. More..
Tuesday, August 29, 2017
Dr Jenny Puetzer (left) and Dr Zoe Hewitt (right) Two regenerative medicine researchers have been recognised for their collaborative research […]More »
Wednesday, June 28, 2017
The EBiSC consortium invites you to the Workshop “Scalability of the iPSC technology for future drug discovery & therapy” on […]More »
Friday, March 31, 2017
The UK Regenerative Medicine Platform (UKRMP), is to receive a further multimillion funding commitment to help realise the goal of […]More »